Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.9M Sell
25,100
-31,800
-56% -$2.39M ﹤0.01% 6171
2025
Q4
$4.24M Sell
56,900
-182,100
-76% -$13.3M ﹤0.01% 4545
2025
Q3
$16.1M Buy
239,000
+67,500
+39% +$4.48M ﹤0.01% 2602
2025
Q2
$11.2M Buy
171,500
+136,300
+387% +$8.17M ﹤0.01% 2875
2025
Q1
$2.17M Sell
35,200
-69,700
-66% -$4.62M ﹤0.01% 5369
2024
Q4
$7.56M Buy
104,900
+63,700
+155% +$4.98M ﹤0.01% 3338
2024
Q3
$3.36M Buy
41,200
+33,600
+442% +$2.69M ﹤0.01% 4601
2024
Q2
$564K Sell
7,600
-23,500
-76% -$1.76M ﹤0.01% 7815
2024
Q1
$2.42M Sell
31,100
-71,200
-70% -$5.3M ﹤0.01% 5155
2023
Q4
$7.31M Buy
102,300
+51,100
+100% +$3.56M ﹤0.01% 3257
2023
Q3
$3.55M Buy
51,200
+9,400
+22% +$710K ﹤0.01% 4193
2023
Q2
$3.38M Sell
41,800
-2,600
-6% -$212K ﹤0.01% 4255
2023
Q1
$3.58M Sell
44,400
-36,400
-45% -$2.93M ﹤0.01% 4359
2022
Q4
$6.04M Buy
80,800
+18,200
+29% +$1.3M ﹤0.01% 3556
2022
Q3
$4.04M Sell
62,600
-13,800
-18% -$956K ﹤0.01% 4237
2022
Q2
$5.29M Buy
76,400
+30,000
+65% +$2.23M ﹤0.01% 3691
2022
Q1
$3.56M Buy
46,400
+10,900
+31% +$784K ﹤0.01% 4837
2021
Q4
$2.72M Buy
35,500
+1,600
+5% +$118K ﹤0.01% 5531
2021
Q3
$2.5M Sell
33,900
-5,900
-15% -$442K ﹤0.01% 5803
2021
Q2
$2.65M Sell
39,800
-17,600
-31% -$1.18M ﹤0.01% 5900
2021
Q1
$4.27M Buy
57,400
+35,200
+159% +$2.67M ﹤0.01% 4619
2020
Q4
$1.62M Buy
22,200
+8,500
+62% +$600K ﹤0.01% 5827
2020
Q3
$911K Sell
13,700
-29,200
-68% -$1.85M ﹤0.01% 6207
2020
Q2
$2.44M Buy
42,900
+3,900
+10% +$191K ﹤0.01% 4206
2020
Q1
$1.37M Sell
39,000
-2,600
-6% -$124K ﹤0.01% 4779
2019
Q4
$2.17M Sell
41,600
-5,100
-11% -$254K ﹤0.01% 4278
2019
Q3
$2.36M Buy
46,700
+41,200
+749% +$2.03M ﹤0.01% 4224
2019
Q2
$264K Sell
5,500
-29,500
-84% -$1.36M ﹤0.01% 7779
2019
Q1
$1.69M Sell
35,000
-5,300
-13% -$239K ﹤0.01% 4737
2018
Q4
$1.66M Buy
40,300
+11,300
+39% +$464K ﹤0.01% 4447
2018
Q3
$1.19M Buy
29,000
+4,700
+19% +$190K ﹤0.01% 5248
2018
Q2
$966K Sell
24,300
-7,200
-23% -$277K ﹤0.01% 5278
2018
Q1
$1.18M Buy
31,500
+11,000
+54% +$444K ﹤0.01% 4555
2017
Q4
$876K Buy
20,500
+2,600
+15% +$104K ﹤0.01% 4840
2017
Q3
$657K Buy
17,900
+8,100
+83% +$327K ﹤0.01% 4932
2017
Q2
$445K Buy
9,800
+1,100
+13% +$48.6K ﹤0.01% 5285
2017
Q1
$370K Sell
8,700
-1,200
-12% -$48.9K ﹤0.01% 5544
2016
Q4
$397K Sell
9,900
-4,100
-29% -$158K ﹤0.01% 5265
2016
Q3
$544K Buy
14,000
+600
+4% +$22.6K ﹤0.01% 4733
2016
Q2
$464K Sell
13,400
-2,800
-17% -$97K ﹤0.01% 4586
2016
Q1
$559K Sell
16,200
-25,200
-61% -$879K ﹤0.01% 4256
2015
Q4
$1.6M Sell
41,400
-24,300
-37% -$945K ﹤0.01% 2995
2015
Q3
$2.57M Buy
65,700
+36,400
+124% +$1.44M ﹤0.01% 2637
2015
Q2
$1.11M Buy
29,300
+9,000
+44% +$315K ﹤0.01% 3813
2015
Q1
$670K Sell
20,300
-10,600
-34% -$325K ﹤0.01% 4492
2014
Q4
$826K Buy
30,900
+3,500
+13% +$90.3K ﹤0.01% 4008
2014
Q3
$667K Buy
27,400
+14,100
+106% +$356K ﹤0.01% 4236
2014
Q2
$337K Sell
13,300
-400
-3% -$9.35K ﹤0.01% 4901
2014
Q1
$295K Sell
13,700
-42,300
-76% -$913K ﹤0.01% 5044
2013
Q4
$1.25M Buy
56,000
+40,300
+257% +$889K ﹤0.01% 3003
2013
Q3
$324K Sell
15,700
-13,300
-46% -$283K ﹤0.01% 4270
2013
Q2
$560K Buy
+29,000
New +$606K ﹤0.01% 3725

Other funds holding HOLX

Citadel Advisors's HOLX Position: Q1 2026 in Review

Citadel Advisors increased its Hologic (HOLX) stake by 71% in Q1 2026, buying an estimated $34M and bringing the position to 1,090,660 shares worth $82.4M. The position accounts for 0.01% of the portfolio, ranked #947.

Citadel Advisors first reported a position in HOLX in Q2 2013 and has held it in 47 quarters since. The position peaked at $434M in Q3 2023. 704 funds tracked by Wall St. Rank hold HOLX as of Q1 2026.

  • Citadel Advisors held 1,090,660 shares of Hologic worth $82.4M as of Q1 2026.
  • Citadel Advisors bought 452,018 Hologic shares in Q1 2026, an estimated $34M.
  • Hologic made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #947 holding.
  • Citadel Advisors first reported a position in Hologic in Q2 2013 and has held it in 47 quarters since.
  • Citadel Advisors's Hologic position peaked at $434M in Q3 2023.
  • 704 funds tracked by Wall St. Rank held Hologic as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.